Innovative Bispecific Nanobody Targeting PDCD1 and VEGF for Advanced Colorectal Cancer Therapy

VHH-P311 is a humanized nanobody-based bispecific antibody designed to simultaneously target programmed cell death 1 (PDCD1) and vascular endothelial growth factors (VEGF). This advanced construct integrates the enhanced specificity of antibody-binding fragments against PDCD1 with single domain antibodies for VEGF, all expressed in CHO-K1 cells. Currently in the Biological Testing stage, VHH-P311 holds promise as a novel therapeutic intervention for colorectal cancer, aiming to address both tumor immune evasion and pathological angiogenesis. Its differentiated mechanism may offer a superior alternative to existing treatment paradigms in this indication.

Licensing Opportunity

VHH-P311 is available for licensing and co-development partnerships. We welcome inquiries from biopharmaceutical companies and research collaborators interested in advancing this innovative bispecific nanobody for colorectal cancer and related clinical applications.

Development Phase

Modality

VHH-P311 is engineered as a bispecific IgG4 antibody, comprising two antibody-binding fragments targeting PDCD1 and single domain nanobodies specifically directed at VEGF, fused to the Fc region for extended half-life. The single domain nanobody components endow the molecule with a reduced molecular size, enhanced tumor penetration, and notable stability, which are critical attributes for targeting solid tumors such as colorectal cancer. Expression in CHO-K1 cells ensures scalable production and human compatibility. This modality, bridging classic antibody fragments with nanobody formats, may translate into improved therapeutic index, better tissue distribution, and synergistic blockade of multiple oncogenic pathways in colorectal tumors.

Target

PDCD1 and VEGF are pivotal molecular targets in the tumor microenvironment. PDCD1 is an immune checkpoint receptor mainly expressed on activated T cells; its engagement dampens antitumor immunity, facilitating immune escape. VEGF, a family of secreted proteins, is a master regulator of angiogenesis, highly expressed in tumor-associated endothelial cells and stroma, promoting vascularization and tumor growth. In colorectal cancer, aberrant VEGF signaling drives neovascularization, while PDCD1-mediated suppression impairs immune surveillance. Targeting both PDCD1 and VEGF disrupts distinct yet complementary pathways in tumor progression. VHH-P311’s dual specificity for PDCD1 and VEGF represents a strategic innovation, offering the potential to inhibit immune evasion and angiogenesis simultaneously, which could result in enhanced antitumor efficacy and broader therapeutic applicability in colorectal cancer management.

Mechanism of Action

VHH-P311 exerts its antitumor effects by simultaneously inhibiting PDCD1 and VEGF. By binding to PDCD1, the molecule blocks inhibitory immune checkpoint signaling, thereby restoring T cell–mediated antitumor responses. Concurrent targeting of VEGF disrupts angiogenesis within the tumor microenvironment, depriving the tumor of essential blood supply and nutrients. This dual-action approach not only enhances immune activation but also impairs tumor vascularization, leading to a more robust inhibition of tumor growth. The modular nanobody platform of VHH-P311 provides flexibility for further engineering, including the potential development of multifunctional biotherapeutics, such as ADCs or alternative bispecifics, expanding its utility across oncology indications.

Colorectal Cancer

Colorectal cancer is among the most prevalent malignancies worldwide and contributes significantly to global cancer-related morbidity and mortality. Its incidence has been steadily rising, especially in regions adopting westernized lifestyles. Current treatment approaches include surgical resection, chemoradiotherapy, immunotherapy, and targeted molecular agents. Despite these advancements, advanced colorectal cancer remains challenging to treat due to frequent metastasis, resistance to chemotherapy, and substantial toxicity associated with existing therapies. Furthermore, immune checkpoint inhibitors and anti-angiogenic agents provide survival benefits in select populations, yet large proportions of patients do not achieve durable responses. There is an urgent need for innovative therapeutics that can overcome immune evasion and pathological angiogenesis simultaneously. VHH-P311, by targeting both PDCD1 and VEGF with a bispecific format, addresses these core mechanisms, representing a promising strategy to meet critical unmet needs in advanced colorectal cancer care.